Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Mobocertinib |
Trade Name | Exkivity |
Synonyms | TAK-788|TAK788|AP32788|AP-32788|AP 32788 |
Drug Descriptions |
Exkivity (mobocertinib) inhibits EGFR and ERBB2 (HER2), with selectivity for mutant forms including EGFR exon 20 insertions, potentially resulting in growth inhibition in EGFR or ERBB2-mutant cancer cells (PMID: 33632775). |
DrugClasses | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 |
CAS Registry Number | 1847461-43-1 |
NCIT ID | C126752 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ado-trastuzumab emtansine + Mobocertinib | Ado-trastuzumab emtansine Mobocertinib | 0 | 0 |
Alisertib + Mobocertinib | Alisertib Mobocertinib | 0 | 0 |
Bevacizumab + Mobocertinib | Bevacizumab Mobocertinib | 0 | 0 |
Cetuximab + Mobocertinib | Cetuximab Mobocertinib | 0 | 0 |
Mobocertinib | Mobocertinib | 0 | 2 |
Mobocertinib + Sapanisertib | Mobocertinib Sapanisertib | 0 | 0 |
Mobocertinib + Trametinib | Mobocertinib Trametinib | 0 | 0 |